



AMENDMENT TRANSMITTAL LETTER					Docket No. 4533-0108PUS1
Application No.		Filing Date		Examiner	Art Unit
10/822,761-Conf. #004958		April 13, 2004		S. McGarry	1635
Applicant(s): Zhio	ing ZHANG et	al.			
nvention: OLIGO (TNF-A		S ANTAGONI	ST FOR HUN	IAN TUMOR NECR	OSIS FACTOR ALPHA
MS Amendment Commissioner for I P.O. Box 1450 Alexandria, VA 223 Transmitted here	313-1450	ndment in the :	above-identif	ed application.	
The fee has been	calculated an	d is transmitted	d as shown b	elow.	
		CLAIM	S AS AMENI	DED	
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	14	- 20 =	0	x 50.00	0.00
Independent Claims	2	- 3 =	0	x 200.00	0.00
Please charge A duplicate of A check in the Payment by	al fee is require ge Deposit Acc copy of this she ne amount of \$ credit card. For is hereby auth	d for this amer count No. eet is enclosed orm PTO-2038 porized to charge	idment. ir is encloris attached. ge and credit	Deposit Account No	0.00



Docket No.: 4533-0108PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Zhiqing ZHANG et al.

Application No.: 10/822,761

Confirmation No.: 004958

Filed: April 13, 2004

Art Unit: 1635

For: OLIGONUCLEOTIDES ANTAGONIST FOR

HUMAN TUMOR NECROSIS FACTOR α

 $(TNF-\alpha)$

Examiner: S. McGarry

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated September 18, 2006, please amend the above-identified U.S. patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 4 of this paper.

Remarks begin on page 9 of this paper.